Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine

Gut

Volumn 67, Issue 6, 2018, Pages 1168-1180

  Ogino, Shuji ^a,b,c,d   Nowak, Jonathan A ^a   Hamada, Tsuyoshi ^b   Phipps, Amanda I ^e,f   Peters, Ulrike ^e,f   Milner, Danny A ^g   Giovannucci, Edward L ^b,c   Nishihara, Reiko ^a,c,d   Giannakis, Marios ^a,b,d   Garrett, Wendy S ^b,c,d   Song, Mingyang ^c,h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g American Society for Clinical Pathology   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; HUMAN; IMMUNOPROPHYLAXIS; MOLECULAR PATHOLOGY; NONHUMAN; PERSONALIZED MEDICINE; POPULATION RESEARCH; PRIORITY JOURNAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES;

IMMUNOLOGIC FACTOR;

ALLERGY AND IMMUNOLOGY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY, MOLECULAR; PRECISION MEDICINE;

EID: 85045665314     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-315537     Document Type: Article

References (291)

1. Galon J, Angell HK, Bedognetti D, et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013;39:11-26.
2. Smyth MJ, Ngiow SF, Ribas A, et al. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2016;13:143-58.
3. Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol 2017;14:155-67.
4. Gubin MM. Cancer Immunology and Immunotherapy: taking a place in mainstream oncology keystone symposia meeting summary. Cancer Immunol Res 2017;5:434-8.
5. Marzbani E, Inatsuka C, Lu H, et al. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res 2013;6:764-73.
6. Melief CJ, van Hall T, Arens R, et al. Therapeutic cancer vaccines. J Clin Invest 2015;125:3401-12.
7. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21.
8. Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017;547:222-6.
9. Kensler TW, Spira A, Garber JE, et al. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res 2016;9:2-10.
10. Blomain ES, Waldman SA. Does obesity promote the development of colorectal cancer? Expert Rev Anticancer Ther 2016;16:465-7.
11. Umar A, Steele VE, Menter DG, et al. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 2016;43:65-77.
12. Friedenreich CM, Neilson HK, Farris MS, et al. Physical activity and cancer outcomes: a precision medicine approach. Clin Cancer Res 2016;22:4766-75.
13. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016;16:173-86.
14. Dou R, Ng K, Giovannucci EL, et al. Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence. Br J Nutr 2016;115:1643-60.
15. Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol 2017;18:843-50.
16. Koelwyn GJ, Quail DF, Zhang X, et al. Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer 2017;17:620-32.
17. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 2015;15:484-98.
18. Palesh O, Demark-Wahnefried W, Mustian K, et al. Conducting cancer control and survivorship research via cooperative groups: a report from the American Society of Preventive Oncology. Cancer Epidemiol Biomarkers Prev 2011;20:1050-5.
19. Kushi LH, Doyle C, McCullough M, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012;62:30-67.
20. Elena JW, Travis LB, Simonds NI, et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst 2013;105:85-94.
21. Spira A, Yurgelun MB, Alexandrov L, et al. Precancer atlas to drive precision prevention trials. Cancer Res 2017;77:1510-41.
22. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9(Suppl 5):S1-32.
23. deLeeuw RJ, Kost SE, Kakal JA, et al. The prognostic value of FoxP3+ tumorinfiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012;18:3022-9.
24. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010;222:350-66.
25. Saito T, Nishikawa H, Wada H, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 2016;22:679-84.
26. Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012;10:205.
27. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014;232:199-209.
28. Wirta EV, Seppälä T, Friman M, et al. Immunoscore in mismatch repair-proficient and -deficient colon cancer. J Pathol Clin Res 2017;3:203-13.
29. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:711-9.
30. Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016;44:698-711.
31. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
32. Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 2016;15:857-65.
33. Li SK, Martin A. Mismatch repair and colon cancer: mechanisms and therapies explored. Trends Mol Med 2016;22:274-89.
34. Taieb J, Le Malicot K, Shi Q, et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J Natl Cancer Inst 2017;109:djw272.
35. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
36. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-13.
37. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
38. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triplenegative breast cancer. Cancer Immunol Res 2014;2:361-70.
39. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-8.
40. Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014;25:590-604.
41. Teng MW, Ngiow SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015;75:2139-45.
42. Zhang Y, Chen L. Classification of advanced human cancers based on Tumor Immunity in the MicroEnvironment (TIME) for cancer immunotherapy. JAMA Oncol 2016;2:1403-4.
43. Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 2003;9:1269-74.
44. Antonioli L, Blandizzi C, Pacher P, et al. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013;13:842-57.
45. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012;72:5435-40.
46. Sippel TR, White J, Nag K, et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res 2011;17:6992-7002.
47. Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014;513:559-63.
48. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-51.
49. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116.
50. Chang CH, Qiu J, O'Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015;162:1229-41.
51. Ioannidis JP. How to make more published research true. PLoS Med 2014;11:e1001747.
52. Ogino S, King EE, Beck AH, et al. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol 2012;176:659-67.
53. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010;102:365-7.
54. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
55. Ogino S, Nishihara R, VanderWeele TJ, et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 2016;27:602-11.
56. Hughes LAE, Simons C, van den Brandt PA, et al. Lifestyle, diet, and colorectal cancer risk according to (epi)genetic instability: current evidence and future directions of molecular pathological epidemiology. Curr Colorectal Cancer Rep 2017;13:455-69.
57. Lochhead P, Chan AT, Giovannucci E, et al. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol 2014;109:1205-14.
58. Roy HK, Turzhitsky V, Wali R, et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut 2017;66:285-92.
59. Lochhead P, Chan AT, Nishihara R, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol 2015;28:14-29.
60. Wang M, Spiegelman D, Kuchiba A, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med 2016;35:782-800.
61. Wang M, Kuchiba A, Ogino S. A Meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol 2015;182:263-70.
62. Chatterjee N, Sinha S, Diver WR, et al. Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika 2010;97:683-98.
63. Chatterjee N. A two-stage regression model for epidemiological studies with multivariate disease classification data. J Am Stat Assoc 2004;99:127-38.
64. Begg CB, Orlow I, Zabor EC, et al. Identifying etiologically distinct sub-types of cancer: a demonstration project involving breast cancer. Cancer Med 2015;4:1432-9.
65. Zabor EC, Begg CB. A comparison of statistical methods for the study of etiologic heterogeneity. Stat Med 2017;36:4050-60.
66. Begg CB, Seshan VE, Zabor EC, et al. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol 2014;14:138.
67. Begg CB, Zabor EC, Bernstein JL, et al. A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med 2013;32:5039-52.
68. Rosner B, Glynn RJ, Tamimi RM, et al. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol 2013;178:296-308.
69. Richiardi L, Barone-Adesi F, Pearce N. Cancer subtypes in aetiological research. Eur J Epidemiol 2017;32:353-61.
70. Nevo D, Nishihara R, Ogino S, et al. The competing risks Cox model with auxiliary case covariates under weaker missing-at-random cause of failure. Lifetime Data Anal 2017. doi: 10.1007/s10985-017-9401-8. [Epub ahead of print 4 Aug 2017].
71. Rescigno T, Micolucci L, Tecce MF, et al. Bioactive nutrients and nutrigenomics in age-related diseases. Molecules 2017;22:e105.
72. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int 2011;2011:1-8.
73. Bishehsari F, Mahdavinia M, Vacca M, et al. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol 2014;20:6055-72.
74. Jiang MJ, Dai JJ, Gu DN, et al. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta 2016;1866:163-76.
75. Martinez-Useros J, Garcia-Foncillas J. Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med 2016;14:21.
76. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer- reinterpreting paradigms. Nat Rev Clin Oncol 2012;9:561-70.
77. Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev 2015;24:1229-38.
78. Serafino A, Sferrazza G, Colini Baldeschi A, et al. Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases. Expert Opin Drug Discov 2017;12:169-86.
79. Patil H, Saxena SG, Barrow CJ, et al. Chasing the personalized medicine dream through biomarker validation in colorectal cancer. Drug Discov Today 2017;22:111-9.
80. Kuroiwa-Trzmielina J, Wang F, Rapkins RW, et al. SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing mgmt-methylated colorectal cancer. Clin Cancer Res 2016;22:6266-77.
81. Slattery ML, Lee FY, Pellatt AJ, et al. Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype. Mod Pathol 2017;30:1152-69.
82. Alnabulsi A, Murray GI. Integrative analysis of the colorectal cancer proteome: potential clinical impact. Expert Rev Proteomics 2016;13:917-27.
83. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012;25:1055-68.
84. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta 2012;1825:77-85.
85. Szylberg E., Janiczek M, Popiel A, et al. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. Gastroenterol Res Pract 2015;2015:1-7.
86. Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers 2015;1:15065.
87. Gao C. Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma. World J Hepatol 2016;8:1119-27.
88. Mehta AM, Osse M, Kolkman-Uljee S, et al. Molecular backgrounds of ERAP1 downregulation in cervical carcinoma. Anal Cell Pathol 2015;2015:1-5.
89. Hagland HR, Berg M, Jolma IW, et al. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg 2013;30:12-25.
90. Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomarkers Prev 2014;23:2694-702.
91. Buchanan DD, Win AK, Walsh MD, et al. Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev 2013;22:917-26.
92. Chen IC, Lee KH, Hsu YH, et al. Expression Pattern and Clinicopathological Relevance of the Indoleamine 2, 3-Dioxygenase 1/Tryptophan 2, 3-Dioxygenase Protein in Colorectal Cancer. Dis Markers 2016;2016:1-9.
93. Lee DH, Keum N, Giovannucci EL. Colorectal Cancer Epidemiology in the Nurses' Health Study. Am J Public Health 2016;106:1599-607.
94. Li YY, Ge QX, Cao J, et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol 2016;22:3227-33.
95. Venniyoor A. The most important questions in cancer research and clinical oncologyquestion 2-5. Obesity-related cancers: more questions than answers. Chin J Cancer 2017;36:18.
96. Li W, Qiu T, Ling Y, et al. Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. Oncotarget 2015;6:39607-13.
97. Zaidi N, Lupien L, Kuemmerle NB, et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 2013;52:585-9.
98. Sampedro GR, Bubeck Wardenburg J. Staphylococcus aureus in the intensive care unit: are these golden grapes ripe for a new approach? J Infect Dis 2017;215:S64-70.
99. Chu SK, Yang HC. Interethnic DNA methylation difference and its implications in pharmacoepigenetics. Epigenomics 2017;9:1437-54.
100. Juárez M, Egoavil C, Rodríguez-Soler M, et al. KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia. PLoS One 2017;12:e0184937.
101. Choi YJ, Lee DH, Han KD, et al. The relationship between drinking alcohol and esophageal, gastric or colorectal cancer: a nationwide population-based cohort study of South Korea. PLoS One 2017;12:e0185778.
102. Dong X, Hou Q, Chen Y, et al. Diagnostic value of the methylation of multiple gene promoters in serum in hepatitis B virus-related hepatocellular carcinoma. Dis Markers 2017;2017:1-6.
103. Wang J, Shen C, Fu Y, et al. The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis. Onco Targets Ther 2017;10:1725-34.
104. Suh SS, Kim TK, Kim JE, et al. Anticancer activity of ramalin, a secondary metabolite from the antarctic lichen ramalina terebrata, against colorectal cancer cells. Molecules 2017;22:1361.
105. Yuan W, Chen J, Shu Y, et al. Correlation of DAPK1 methylation and the risk of gastrointestinal cancer: a systematic review and meta-analysis. PLoS One 2017;12:e0184959.
106. Szpiech ZA, Strauli NB, White KA, et al. Prominent features of the amino acid mutation landscape in cancer. PLoS One 2017;12:e0183273.
107. Zhu CS, Huang WY, Pinsky PF, et al. The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial pathology tissue resource. Cancer Epidemiol Biomarkers Prev 2016;25:1635-42.
108. Ciesielski TH, Aldrich MC, Marsit CJ, et al. Transdisciplinary approaches enhance the production of translational knowledge. Transl Res 2017;182:123-34.
109. Kuller LH. Commentary: epidemiology - then and now. Am J Epidemiol 2016;183:372-80.
110. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017;14:9-32.
111. Lewis C, McQuaid S, Hamilton PW, et al. Building a 'repository of science': the importance of integrating biobanks within molecular pathology programmes. Eur J Cancer 2016;67:191-9.
112. Ryan E, Sheahan K, Creavin B, et al. The current value of determining the mismatch repair status of colorectal cancer: a rationale for routine testing. Crit Rev Oncol Hematol 2017;116:38-57.
113. Micolucci L, Rippo MR, Olivieri F, et al. Progress of research on microRNAs with diagnostic value in asbestos exposure: a call for method standardization. Biosci Trends 2017;11:105-9.
114. Ogino S, 2013. Molecular pathological epidemiology (MPE): Overview of its paradigm and wide applicability even without tumor tissue [abstract]. Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research. National Harbor, MD:Cancer Prev Res (Phila);27-30 Oct 2013;6: CN06-1
115. Kuller LH, Bracken MB, Ogino S, et al. The role of epidemiology in the era of molecular epidemiology and genomics: summary of the 2013 AJEsponsored Society of Epidemiologic Research Symposium. Am J Epidemiol 2013;178:1350-4.
116. Epplein M, Bostick RM, Mu L, et al. Challenges and opportunities in international molecular cancer prevention research: an ASPO molecular epidemiology and the environment and international cancer prevention interest groups report. Cancer Epidemiol Biomarkers Prev 2014;23:2613-7.
117. Ogino S, 2017. Molecular pathological epidemiology of risk factors and CRC microbial and immune characteristics. [abstract]. Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes. Tampa, FL:Cancer Res;17-20 Sep 2016;77: IA28
118. Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control 2015;26:959-72.
119. Campbell PT, Rebbeck TR, Nishihara R, et al. Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control 2017;28:167-76.
120. Drew DA, Chin SM, Gilpin KK, et al. ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials 2017;18:50.
121. Frouws MA, van Herk-Sukel MPP, Maas HA, et al. The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence. Cancer Treat Rev 2017;55:120-7.
122. Herbert K, Kerr R, Kerr DJ, et al. Are NSAIDs coming back to colorectal cancer therapy or not? Curr Colorectal Cancer Rep 2014;10:363-71.
123. Tougeron D, Sha D, Manthravadi S, et al. Aspirin and colorectal cancer: back to the future. Clin Cancer Res 2014;20:1087-94.
124. Hua X, Phipps AI, Burnett-Hartman AN, et al. Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival. J Clin Oncol 2017;35:2806-13.
125. Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 2015;64:1419-25.
126. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
127. Gray RT, Cantwell MM, Coleman HG, et al. Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study. Clin Transl Gastroenterol 2017;8:e91.
128. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
129. Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from NSAID therapy in colorectal cancer. J Clin Oncol 2013;31:4297-305.
130. Mei ZB, Duan CY, Li CB, et al. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2016;27:1836-48.
131. Hamada T, Cao Y, Qian ZR, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J Clin Oncol 2017;35:1836-44.
132. Stewart BW, Bray F, Forman D, et al. Cancer prevention as part of precision medicine: 'plenty to be done'. Carcinogenesis 2016;37:2-9.
133. Meyskens FL, Mukhtar H, Rock CL, et al. Cancer prevention: obstacles, challenges and the road ahead. J Natl Cancer Inst 2016;108:djv309.
134. Wild CP, Bucher JR, de Jong BW, et al. Translational cancer research: balancing prevention and treatment to combat cancer globally. J Natl Cancer Inst 2015;107:1-5.
135. Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006;131:1700-5.
136. Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol 2010;105:1189-95.
137. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-105.
138. Stoffel EM, Erichsen R, Frøslev T, et al. Clinical and molecular characteristics of post-colonoscopy colorectal cancer: a population-based study. Gastroenterology 2016;151:870-8.
139. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006;98:1731-8.
140. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010;102:1012-22.
141. Poynter JN, Haile RW, Siegmund KD, et al. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 2009;18:2745-50.
142. Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol 2013;178:84-100.
143. Rozek LS, Herron CM, Greenson JK, et al. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010;19:838-43.
144. Nishi A, Milner DA, Giovannucci EL, et al. Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn 2016;16:11-23.
145. Hamada T, Keum N, Nishihara R, et al. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol 2017;52:265-75.
146. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42.
147. Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013;309:2563-71.
148. Fink SP, Yamauchi M, Nishihara R, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014;6:233re2.
149. Ogino S, Jhun I, Mata DA, et al. Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology. NPJ Precis Oncol 2017;1:40.
150. Nishihara R, VanderWeele TJ, Shibuya K, et al. Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol 2015;30:1129-35.
151. Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer 2013;132:625-34.
152. Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 2013;105:1862-70.
153. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013;26:465-84.
154. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-8.
155. van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42.
156. Basile D, Garattini SK, Bonotto M, et al. Immunotherapy for colorectal cancer: where are we heading? Expert Opin Biol Ther 2017;17:709-21.
157. Cramer DW, Finn OJ. Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 2011;23:265-71.
158. Rocca YS, Roberti MP, Arriaga JM, et al. Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun 2013;19:76-85.
159. Raine T, Liu JZ, Anderson CA, et al. Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immunemediated disease. Gut 2015;64:250-9.
160. Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
161. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-85.
162. Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep 2015;3:269-76.
163. Kudryavtseva AV, Lipatova AV, Zaretsky AR, et al. Important molecular genetic markers of colorectal cancer. Oncotarget 2016;7:53959-83.
164. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015;148:77-87.
165. Bijlsma MF, Sadanandam A, Tan P, et al. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2017;14:333-42.
166. Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017;17:79-92.
167. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn 2017;19:187-225.
168. Giannakis M, Hodis E, Jasmine Mu X, Mu J, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet 2014;46:1264-6.
169. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
170. Di Caro G, Marchesi F, Laghi L, et al. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med 2013;17:1088-95.
171. Koshiol J, Lin SW. Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol 2012;22:520-30.
172. Drewes JL, Housseau F, Sears CL. Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy. Br J Cancer 2016;115:273-80.
173. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8:686-700.
174. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers 2013;5:676-713.
175. Zoratto F, Rossi L, Verrico M, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. Tumour Biol 2014;35:6195-206.
176. Okugawa Y, Grady WM, Goel A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology 2015;149:1204-25.
177. Ng JM, Yu J. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci 2015;16:2472-96.
178. Suzuki H, Yamamoto E, Maruyama R, et al. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun 2014;455:35-42.
179. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-54.
180. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer: a tale of two sides or a continuum? Gut 2012;61:794-7.
181. Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 2013;109:1004-12.
182. Jess P, Hansen IO, Gamborg M, et al. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open 2013;3:e002608.
183. Rosty C, Young JP, Walsh MD, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013;26:825-34.
184. Rosty C, Young JP, Walsh MD, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One 2013;8:e65479.
185. Phipps AI, Buchanan DD, Makar KW, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2012;21:1792-8.
186. Ito M, Mitsuhashi K, Igarashi H, et al. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. Int J Cancer 2014;135:2507-15.
187. Mima K, Cao Y, Chan AT, et al. Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol 2016;7:e200.
188. Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Canc Netw 2017;15:411-9.
189. Nishihara R, Glass K, Mima K, et al. Biomarker correlation network in colorectal carcinoma by tumor anatomic location. BMC Bioinformatics 2017;18:304.
190. Loree JM, Pereira AAL, Lam M, et al. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res 2018;24:1062-72.
191. Phipps AI, Chan AT, Ogino S. Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer 2013;119:3140-7.
192. Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233-42.
193. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74.
194. Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2017;66:1463-73.
195. Lee KS, Kwak Y, Ahn S, et al. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunol Immunother 2017;66:927-39.
196. Inaguma S, Lasota J, Wang Z, et al. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol 2017;30:278-85.
197. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, et al. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016;29:1104-12.
198. Lee LH, Cavalcanti MS, Segal NH, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol 2016;29:1433-42.
199. Koganemaru S, Inoshita N, Miura Y, et al. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. Cancer Sci 2017;108:853-8.
200. Marisa L, Svrcek M, Collura A, et al. The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. J Natl Cancer Inst 2018;110:68-77.
201. Inaguma S, Lasota J, Felisiak-Golabek A, et al. Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. J Pathol Clin Res 2017;3:268-78.
202. Masugi Y, Nishihara R, Hamada T, et al. Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaciton to colorecal cancer. Cancer Immunol Res 2017;5:1046-55.
203. Kim JH, Kang GH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol 2014;20:4230-43.
204. Benson AB, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017;15:370-98.
205. Le DT, Hubbard-Lucey VM, Morse MA, et al. A blueprint to advance colorectal cancer immunotherapies. Cancer Immunol Res 2017;5:942-9.
206. Lin JH, Giovannucci E. Environmental exposure and tumor heterogeneity in colorectal cancer risk and outcomes. Curr Colorectal Cancer Rep 2014;10:94-104.
207. Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet 2016;7:105-14.
208. Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15:6412-20.
209. Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012;7:e47045.
210. Ling A, Lundberg IV, Eklöf V, et al. The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. J Pathol Clin Res 2016;2:21-31.
211. Ling A, Edin S, Wikberg ML, et al. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer 2014;110:2551-9.
212. Wangefjord S, Sundström M, Zendehrokh N, et al. Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biol Sex Differ 2013;4:17.
213. Rozek LS, Schmit SL, Greenson JK, et al. Tumor-infiltrating lymphocytes, crohn's-like lymphoid reaction, and survival from colorectal cancer. J Natl Cancer Inst 2016;108.
214. Mima K, Nishihara R, Nowak JA, et al. MicroRNA MIR21 and T cells in colorectal cancer. Cancer Immunol Res 2016;4:33-40.
215. Dou R, Nishihara R, Cao Y, et al. MicroRNA let-7, T Cells, and patient survival in colorectal cancer. Cancer Immunol Res 2016;4:927-35.
216. Kosumi K, Masugi Y, Yang J, et al. Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. Oncoimmunology 2017;6:e1284720.
217. Prizment AE, Vierkant RA, Smyrk TC, et al. Cytotoxic T-cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev 2017;26:622-31.
218. Berntsson J, Svensson MC, Leandersson K, et al. The clinical impact of tumourinfiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study. Int J Cancer 2017;141:1654-66.
219. Prizment AE, Vierkant RA, Smyrk TC, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study. Mod Pathol 2016;29:516-27.
220. Song M, Nishihara R, Cao Y, et al. Marine .-3 polyunsaturated fatty acid intake and risk of colorectal cancer characterized by tumor-infiltrating T cells. JAMA Oncol 2016;2:1197-206.
221. Khalili H, Gong J, Brenner H, et al. Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis 2015;36:999-1007.
222. Peters U, Bien S, Zubair N. Genetic architecture of colorectal cancer. Gut 2015;64:1623-36.
223. Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut 2016;65:296-304.
224. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res 2013;22:278-95.
225. Liu L, Nevo D, Nishihara R, et al. Utility of inverse probability weighting in molecular pathological epidemiology. Eur J Epidemiol 2017. doi: 10.1007/s10654-017-0346-8. [Epub ahead of print 20 Dec 2017].
226. Ogino S, Lochhead P, Giovannucci E, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014;33:2949-55.
227. Hackl H, Charoentong P, Finotello F, et al. Computational genomics tools for dissecting tumour-immune cell interactions. Nat Rev Genet 2016;17:441-58.
228. Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013;4:2612.
229. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938-45.
230. Benichou J, Ben-Hamo R, Louzoun Y, et al. Rep-Seq: uncovering the immunological repertoire through next-generation sequencing. Immunology 2012;135:183-91.
231. Safonova Y, Lapidus A, Lill J. IgSimulator: a versatile immunosequencing simulator. Bioinformatics 2015;31:3213-5.
232. Howie B, Sherwood AM, Berkebile AD, et al. High-throughput pairing of T cell receptor a and ß sequences. Sci Transl Med 2015;7:301ra131.
233. Li B, Li T, Pignon JC, et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet 2016;48:725-32.
234. Sako T, Kudo SE, Miyachi H, et al. A novel ability of endocytoscopy to diagnose histological grade of differentiation in T1 colorectal carcinomas. Endoscopy 2018;50:69-74.
235. Tearney GJ, Kang D. Introduction to biomedical optical imaging. Lasers Surg Med 2017;49:214.
236. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012;107:1315-29.
237. Haumaier F, Sterlacci W, Vieth M. Histological and molecular classification of gastrointestinal polyps. Best Pract Res Clin Gastroenterol 2017;31:369-79.
238. Ryan BM, Faupel-Badger JM. The hallmarks of premalignant conditions: a molecular basis for cancer prevention. Semin Oncol 2016;43:22-35.
239. Bettington M, Walker N, Rosty C, et al. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. Gut 2017;66:97-106.
240. Prakadan SM, Shalek AK, Weitz DA. Scaling by shrinking: empowering single-cell 'omics' with microfluidic devices. Nat Rev Genet 2017;18:345-61.
241. Bromham L, Dinnage R, Hua X. Interdisciplinary research has consistently lower funding success. Nature 2016;534:684-7.
242. Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochem Biophys Res Commun 2014;455:70-83.
243. Zhou L, Wang K, Li Q, et al. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives. Expert Rev Proteomics 2016;13:367-81.
244. Thiele JA, Bethel K, Králícková M, et al. Circulating tumor cells: fluid surrogates of solid tumors. Annu Rev Pathol 2017;12:419-47.
245. Townsend MK, Aschard H, De Vivo I, et al. Genomics, telomere length, epigenetics, and metabolomics in the nurses health studies. Am J Public Health 2016;106:1663-8.
246. Tan CR, Zhou L, El-Deiry WS. Circulating tumor cells versus circulating tumor DNA in colorectal cancer: pros and cons. Curr Colorectal Cancer Rep 2016;12:151-61.
247. Grillet F, Bayet E, Villeronce O, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut 2017;66:1802-10.
248. Olmedillas López S, García-Olmo DC, García-Arranz M, et al. KRAS G12V mutation detection by droplet digital PCR in circulating cell-free DNA of colorectal cancer patients. Int J Mol Sci 2016;17:484.
249. Nagai Y, Sunami E, Yamamoto Y, et al. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget 2017;8:11906-16.
250. Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14:531-48.
251. Strickler JH, Loree JM, Ahronian LG, et al. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov 2018;8:164-73.
252. Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 2015;9:1773-82.
253. Khagi Y, Goodman AM, Daniels GA, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res 2017;23:5729-36.
254. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016;535:75-84.
255. Chen J, Domingue JC, Sears CL. Microbiota dysbiosis in select human cancers: Evidence of association and causality. Semin Immunol 2017;32:25-34.
256. Chen J, Pitmon E, Wang K. Microbiome, inflammation and colorectal cancer. Semin Immunol 2017;32:43-53.
257. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-8.
258. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22:299-306.
259. Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A 2014;111:18321-6.
260. Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun 2015;6:8727.
261. Nosho K, Sukawa Y, Adachi Y, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016;22:557-66.
262. Yamaoka Y, Suehiro Y, Hashimoto S, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol 2017. doi: 10.1007/s00535-017-1382-6. [Epub ahead of print 19 Aug 2017].
263. Purcell RV, Visnovska M, Biggs PJ, et al. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep 2017;7:11590.
264. Abed J, Emgård JE, Zamir G, et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 2016;20:215-25.
265. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207-15.
266. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T-cells in colorectal carcinoma. JAMA Oncol 2015;1:653-61.
267. East JE, Atkin WS, Bateman AC, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut 2017;66:1181-96.
268. Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015;137:1258-68.
269. Park CH, Han DS, Oh YH, Yh O, et al. Role of Fusobacteria in the serrated pathway of colorectal carcinogenesis. Sci Rep 2016;6:25271.
270. IJspeert JE, Vermeulen L, Meijer GA, et al. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol 2015;12:401-9.
271. Mehta RS, Nishihara R, Cao Y, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue. JAMA Oncol 2017;3:921-7.
272. Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014;74:1311-8.
273. Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016;65:1973-80.
274. Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017;358:1443-8.
275. Mima K, Ogino S, Nakagawa S, et al. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg Oncol 2017;26:368-76.
276. Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2017;66:70-8.
277. Flemer B, Warren RD, Barrett MP, et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut 2017. doi: 10.1136/gutjnl-2017-314814. [Epub ahead of print 7 Oct 2017].
278. Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol 2015;12:732-42.
279. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084-9.
280. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079-84.
281. Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017;170:548-63.
282. Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 2017;357:1156-60.
283. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97-103.
284. Cao Y, Wu K, Mehta R, et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut 2018;67:672-8.
285. Ashktorab H, Kupfer SS, Brim H, et al. Racial disparity in gastrointestinal cancer risk. Gastroenterology 2017;153:910-23.
286. Augustus GJ, Ellis NA. Race in cancer health disparities theme issue colorectal cancer disparity in African Americans: risk factors and carcinogenic mechanisms. Am J Pathol. In Press. 2017.
287. Gardner K. The Science of Cancer Health Disparities: A Young Discipline with an Old Heritage. Am J Pathol 2018;188:268-70.
288. Jaffee EM, Dang CV, Agus DB, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol 2017;18:e653-706.
289. Cao Y, Nishihara R, Qian ZR, et al. Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology 2016;151:879-92.
290. Hanyuda A, Ogino S, Qian ZR, et al. Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer 2016;139:854-68.
291. Liu L, Nishihara R, Qian ZR, et al. Association between inflammatory diet pattern and risk of colorectal carcinoma subtypes classified by immune responses to tumor. Gastroenterology 2017;153:1517-30.